April 27–28, Boston, USA — CATUG will showcase its one-stop mRNA CMC solutions at mRNA Conference 2026 and deliver a featured presentation, sharing insights into mRNA development and IND advancement.
01 | Booth
Visit the CATUG booth to explore mRNA development, CMC strategies, and collaboration opportunities. Learn about our end-to-end capabilities from R&D to GMP manufacturing and regulatory support.
02 | Presentation
Topic: Key CMC Considerations for mRNA Therapeutics Towards IND Approval
Key Points:
03 | Speaker
Aaron Chung | CATUG Biotechnology
Aaron Chung drives global expansion for CATUG Biotechnology’s mRNA CDMO platform, focusing on end-to-end CMC development and IIT/IND-enabling capabilities for mRNA therapeutics. The platform spans process development, GMP manufacturing, and regulatory readiness to support clients across the full mRNA lifecycle.
Previously, Aaron was Founder and CEO of Spindle Biotech Inc., which was acquired by Applied DNA Sciences (NASDAQ: APDN), where he later served as Nucleic Acid Platform Director, gaining deep senior experience in RNA and mRNA process development and manufacturing. He holds a BASc in Electrical Engineering from the University of Waterloo, and bridges cross-disciplinary technical expertise with a track record of scaling biotech innovation from R&D to commercialization.